3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow nirsevimab: new trials by email Literature Review of nirsevimab trials Research Report on nirsevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab Nirsevimab - Respiratory Syncytial Virus Infections | Phase 3 | Completed | AstraZeneca | 33 | 2023-07-27 | 2026-04-16 |
| Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life Nirsevimab - RSV Immunization, Healthy Volunteer | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 8057 | 2022-08-08 | 2025-10-09 |
| Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China Nirsevimab, Placebo - Lower Respiratory Tract Infection | Phase 3 | Completed | AstraZeneca | 800 | 2021-11-24 | 2026-10-15 |
Respiratory Syncytial Virus Infections (1)
AstraZeneca (2) · Sanofi Pasteur, a Sanofi Company (1)
China (1) · France (1) · Germany (1) · Japan (1) · United Kingdom (1)
2025 (1)